Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What is Monogastric Digestion?01:50

What is Monogastric Digestion?

73.4K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
73.4K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

426
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
426
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

272
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
272
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

389
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
389

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Facilitating access to clinical data from a randomized controlled trial of complex adaptive design.

BMC research notes·2026
Same author

Beyond Viral Control: Tenofovir's Hidden Impact on Blood-Brain Barrier Endothelial Cells.

Microcirculation (New York, N.Y. : 1994)·2026
Same author

A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Chitosan-hyaluronic acid engineered polycaprolactone nanoparticles enhance curcumin antiplasmodial activity and preserve blood-brain barrier integrity.

Journal of biomaterials science. Polymer edition·2026
Same author

Development of a prediction model for acute kidney injury in critically ill patients with advanced colorectal cancer based on white blood cell-related indicators.

Frontiers in oncology·2026
Same author

Progressive Hypoxia Exacerbates Breast Cancer Metastasis by Paracrine Modulation of the Blood-brain Barrier Endothelium.

Journal of molecular neuroscience : MN·2026

Related Experiment Video

Updated: Nov 3, 2025

Murine Fecal Isolation and Microbiota Transplantation
07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

4.7K

Treating the Metabolic Syndrome by Fecal Transplantation-Current Status.

Stephen D H Malnick1, David Fisher1, Marina Somin1

  • 1Department of Internal Medicine Cj Kaplan Medical Center, The Hebrew University, Rehovot 76100, Israel.

Biology
|June 2, 2021
PubMed
Summary

Fecal microbiota transplantation (FMT) can restore the intestinal microbiome, potentially improving metabolic syndrome and fatty liver disease. This therapy, initially for C. difficile infection, shows promise for broader gut health applications.

Keywords:
fecal transplantationinflammatory mediatorsmetabolic syndromemetabolic-associated fatty liver diseasemicrobiomenon-alcoholic fatty liver disease

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.1K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.4K

Related Experiment Videos

Last Updated: Nov 3, 2025

Murine Fecal Isolation and Microbiota Transplantation
07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

4.7K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.1K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.4K

Area of Science:

  • Gastroenterology and Hepatology
  • Microbiology
  • Metabolic Diseases

Background:

  • The intestinal microbiome (IM) plays a crucial role in gastrointestinal and systemic health.
  • Dysbiosis and altered gut motility contribute to conditions like irritable bowel syndrome (IBS) and increased intestinal permeability.
  • Metabolic syndrome and metabolic-associated fatty liver disease (MAFLD) are significant health concerns linked to fecal microbiome disturbances.

Purpose of the Study:

  • To review the composition and inflammatory changes associated with the intestinal microbiome.
  • To explore the impact of fecal transplantation on metabolic syndrome and MAFLD.
  • To discuss the clinical indications for fecal transplantation.

Main Methods:

  • Literature review of studies on intestinal microbiome composition and function.
  • Analysis of evidence regarding fecal transplantation's effects on metabolic syndrome and MAFLD.
  • Discussion of established and emerging clinical applications of fecal transplantation.

Main Results:

  • Alterations in the intestinal microbiome are implicated in various GI disorders and metabolic diseases.
  • Fecal transplantation is an established treatment for recurrent *Clostridioides difficile* infection.
  • Emerging evidence suggests fecal transplantation may positively influence metabolic syndrome and MAFLD.

Conclusions:

  • The intestinal microbiome's composition is critical for overall health, with dysbiosis linked to inflammation and disease.
  • Fecal transplantation offers a therapeutic strategy for restoring microbial balance.
  • Further research is warranted to fully elucidate the benefits and indications of fecal transplantation for metabolic disorders.